BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30277099)

  • 21. Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.
    Rai S; Tanizawa Y; Cai Z; Huang YJ; Taipale K; Tajimi M
    Adv Ther; 2022 Oct; 39(10):4792-4807. PubMed ID: 35984628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada.
    Anglin P; Elia-Pacitti J; Eberg M; Muratov S; Kukaswadia A; Sharma A; Ewara EM
    Curr Oncol; 2023 Jun; 30(6):5529-5545. PubMed ID: 37366901
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
    Krüger WH; Hirt C; Basara N; Sayer HG; Behre G; Fischer T; Grobe N; Maschmeyer G; Neumann T; Schneidewind L; Niederwieser D; Dölken G; Schmidt CA
    Ann Hematol; 2021 Jun; 100(6):1569-1577. PubMed ID: 33829299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
    Nazeef M; Kahl BS
    Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry
    Obr A; Prochazka V; Papajik T; Klener P; Janikova A; Salek D; Belada D; Pytlík R; Sykorova A; Mocikova H; Simkovic M; Campr V; Dlouha J; Furst T; Trněný M
    Leuk Lymphoma; 2019 Mar; 60(3):748-755. PubMed ID: 30188225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue.
    Salhotra A; Shan Y; Tsai NC; Sanchez JF; Aldoss I; Ali H; Paris T; Spielberger R; Cao TM; Nademanee A; Forman SJ; Chen R
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1264-1268. PubMed ID: 28434928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.
    Dreger P; Rieger M; Seyfarth B; Hensel M; Kneba M; Ho AD; Schmitz N; Pott C
    Haematologica; 2007 Jan; 92(1):42-9. PubMed ID: 17229634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.
    Cohen JB; Han X; Jemal A; Ward EM; Flowers CR
    Cancer; 2016 Aug; 122(15):2356-63. PubMed ID: 27153197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A medicare database analysis of practice patterns in patients with mantle cell lymphoma.
    Weaver JA; Peng Y; Ji Y; Gilbertson D; Pease DF; Morrison VA
    J Geriatr Oncol; 2021 Jul; 12(6):894-901. PubMed ID: 33423932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study.
    Drach J; Huang H; Samoilova O; Belch A; Farber C; Bosly A; Novak J; Zaucha J; Dascalescu A; Bunworasate U; Masliak Z; Vilchevskaya K; Robak T; Pei L; Rooney B; van de Velde H; Cavalli F
    Leuk Lymphoma; 2018 Apr; 59(4):896-903. PubMed ID: 29338540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma.
    van Keep M; Gairy K; Seshagiri D; Thilakarathne P; Lee D
    BMC Cancer; 2016 Aug; 16(1):598. PubMed ID: 27488675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
    Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
    Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
    Wang ML; Jain P; Zhao S; Lee HJ; Nastoupil L; Fayad L; Ok CY; Kanagal-Shamanna R; Hill HA; Yao Y; Hagemeister FB; Westin JR; Fowler N; Samaniego F; Steiner R; Nair R; Iyer SP; Navsaria L; Badillo M; ; Feng L; Xuelin H; Nogueras Gonzalez GM; Xu G; Wagner-Bartak N; Thirumurthi S; Santos D; Tang G; Lin P; Wang SA; Jorgensen J; Yin CC; Li S; Patel KP; Vega F; Medeiros LJ; Flowers CR; Wang L
    Lancet Oncol; 2022 Mar; 23(3):406-415. PubMed ID: 35074072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes.
    Castellino A; Wang Y; Larson MC; Maurer MJ; Link BK; Farooq U; Feldman AL; Syrbu SI; Habermann TM; Paludo J; Inwards DJ; Witzig TE; Ansell SM; Allmer C; Slager SL; Cohen JB; Martin P; Cerhan JR; Nowakowski GS
    Blood Adv; 2022 Feb; 6(4):1350-1360. PubMed ID: 34662895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
    Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
    Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.